Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00287079 | A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome | PHASE3 | COMPLETED | 35 | — | — | Oct 1, 2005 | Nov 1, 2008 | Dec 27, 2013 | 1 | Canada |
CDMS was defined by the occurrence of a second exacerbation or relapse over 96 weeks in participants who presented with Clinically Isolated Syndrome (CIS) accompanied by an abnormal Magnetic Resonance Imaging (MRI) scan. Time was calculated from the date of the stabilization of the baseline CIS episode to the qualifying relapse for the CDMS.
| Arm | Type | Description |
|---|---|---|
| Rebif® | EXPERIMENTAL | - |
| No Treatment | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Rebif® | DRUG | 44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks |
| No Treatment | OTHER | No treatment for 96 weeks |
Inclusion Criteria: * Subject must have experienced a first clinical episode suggestive of demyelinating disease * Subject must present with an abnormal MRI displaying at least 3 T2 weighted hyperintense lesions typical of multiple sclerosis (MS) * Subject must be greater than or equal to 18 years ...